Company news
60 Degrees Pharmaceuticals, Inc. news in 2026
60 Degrees Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
November 4, 2026
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
October 28, 2026
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
October 27, 2026
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
October 6, 2026
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
October 2, 2026
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
October 1, 2026
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
August 17, 2026
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
July 30, 2026
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
July 29, 2026
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
July 7, 2026
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
July 1, 2026
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
June 11, 2026
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
May 26, 2026
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
May 15, 2026
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
April 14, 2026
60 Degrees Pharmaceuticals Announces 2025 Annual Results
March 30, 2026
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
March 17, 2026
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
March 10, 2026
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
February 2, 2026
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
January 28, 2026
60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
January 22, 2026
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
January 15, 2026
Decks in 2026
- 2026 ILADS Annual Scientific Conference
Conference · 29 slides · Oct 23, 2026
- Technical Presentation (October 2026)
Technical · 18 slides · Oct 6, 2026
- H.C. Wainwright Presentation September 2026
Conference · 19 slides · Sep 8, 2026
- Investor Presentation (July 2026)
Investor deck · 30 slides · Jul 20, 2026
- Investor Presentation (January 2026)
Investor deck · 26 slides · Jan 8, 2026